I switched from injectable to oral semaglutide for travel reasons and the fasting window is proving harder to hold than the injection ever was.
So the question, as narrowly as I can put it: whether the fasting requirement is as strict in practice as the label implies, and what people actually see when they get it wrong.
I have searched first, so if this is covered somewhere point me at it and I will read it.
Taking the question as asked, rather than the general version of it. Orforglipron is the more interesting oral story because it is not a peptide at all. Being a small molecule it does not need SNAC, does not need the fasting window, and has oral bioavailability in the tens of percent rather than about one.
SarahChen_PharmD said:Orforglipron is the more interesting oral story because it is not a peptide at all.
That is correct as far as it goes, and here is where it stops going. The absorption variability is real, but it partly averages out over weeks — the steady-state trough is less erratic than any single day would suggest. Where it bites is in the first fortnight, when people conclude the tablet does nothing.
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View Resultsnick_SD_fit said:I switched from injectable to oral semaglutide for travel reasons and the fasting window is proving harder to hold than the injection ever was.
This matches mine closely enough to be worth saying so. The OASIS programme put 50mg oral in the same territory as 2.4mg injectable — around 15% mean weight loss — but it needed a dose 20 times larger to get there because almost none of the tablet is absorbed. The dose numbers are not comparable across routes and quoting them side by side confuses people.
Adding the clinical framing, because it changes how the question reads. The mechanism and the magnitude are separate questions. Agreeing that something happens says nothing about whether it happens enough to act on.